NRAS and colorectal carcinoma: The best approach to guide anti-EGFR treatment decision in SP-CRC with metastatic disease would be to test the metastatic tissue for KRAS and NRAS mutations, because it is not possible to be certain which primary SP-CRC lesion led to the metastasis without any additional study.